Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Interventional × Meibomian Gland Dysfunction × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Conditions

Breast Neoplasms 342 Neoplasms 222 Carcinoma, Non-Small-Cell Lung 202 Prostatic Neoplasms 170 Colorectal Neoplasms 127 Lung Neoplasms 117 Pancreatic Neoplasms 116 Leukemia, Myeloid, Acute 116 Neoplasm Metastasis 113 Multiple Myeloma 107 Lymphoma 103 Carcinoma, Hepatocellular 100 Ovarian Neoplasms 84 Melanoma 84 Head and Neck Neoplasms 82 Leukemia 80 Recurrence 78 Brain Neoplasms 77 Leukemia, Lymphocytic, Chronic, B-Cell 74 Glioblastoma 69 Precursor Cell Lymphoblastic Leukemia-Lymphoma 66 Lymphoma, Non-Hodgkin 65 Squamous Cell Carcinoma of Head and Neck 64 Lymphoma, Follicular 62 Colonic Neoplasms 61 Lymphoma, Large B-Cell, Diffuse 60 Hematologic Neoplasms 51 Rectal Neoplasms 49 Carcinoma, Renal Cell 49 Urinary Bladder Neoplasms 45

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01763437 2017-01-12

TET

The Cleveland Clinic

Phase EARLY_PHASE1 Withdrawn

Meibomian Gland Dysfunction, Rosacea, Chalazion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡